6.4.8 Guidelines for the first-line treatment of hormone-sensitive metastatic disease*,
Recommendations,Strength rating
At the start of ADT offer luteinising hormone-releasing hormone (LHRH) antagonists   or orchiectomy to patients with impending clinical complications like spinal cord   compression or bladder outlet obstruction.,Strong
Offer docetaxel only in combination with ADT plus abiraterone or darolutamide to   patients with M1 disease and who are fit for docetaxel.,Strong
Offer ADT combined with non-curative prostate radiotherapy (using doses up to   the equivalent of 72 Gy in 2 Gy fractions) to patients whose first presentation is M1   disease and who have low volume of disease by CHAARTED criteria/M1a disease.,Strong
